• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by BrainsWay Ltd.

    2/23/26 8:52:22 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care
    Get the next $BWAY alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Brainsway Ltd.

    (Name of Issuer)


    American Depositary Shares, each representing two Ordinary Shares, par value NIS 0.04 per share

    (Title of Class of Securities)


    10501L106

    (CUSIP Number)


    02/16/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    10501L106


    1Names of Reporting Persons

    Harel Insurance Investments & Financial Services Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ISRAEL
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,974,472.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,981,714.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,981,714.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  With regard to Rows (6), (8) and (9), please see Item 4. Row (11) is based on 37,789,726 Ordinary Shares issued and outstanding as of June 30, 2025 (as reported by the Issuer in Exhibit 99.1 to its Report on Form 6-K filed with the Securities and Exchange Commission on September 30, 2025). This CUSIP number above applies to the American Depositary Shares, evidenced by American Depositary Receipts, each representing two Ordinary Shares, par value NIS 0.04 per share. It is hereby clarified that the shares being reported in this Statement as beneficially owned by the Reporting Person are in the form of Ordinary Shares.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Brainsway Ltd.
    (b)Address of issuer's principal executive offices:

    16 Hartum Street, RAD Tower, 14th Floor, Har HaHotzvim, Jerusalem, Israel, 9777516
    Item 2. 
    (a)Name of person filing:

    Harel Insurance Investments & Financial Services Ltd.
    (b)Address or principal business office or, if none, residence:

    3 Aba Hillel Street, Ramat Gan 52118, Israel
    (c)Citizenship:

    Israel
    (d)Title of class of securities:

    American Depositary Shares, each representing two Ordinary Shares, par value NIS 0.04 per share
    (e)CUSIP No.:

    10501L106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Of the 1,981,714 Ordinary Shares reported in this Statement as beneficially owned by the Reporting Person, (i) 1,974,472 Ordinary Shares are held for members of the public through, among others, provident funds and/or mutual funds and/or pension funds and/or insurance policies and/or exchange traded funds, which are managed by subsidiaries of the Reporting Person, each of which subsidiaries operates under independent management and makes independent voting and investment decisions and (ii) 7,242 Ordinary Shares are held by third-party client accounts managed by a subsidiary of the Reporting Person as portfolio managers, which subsidiary operates under independent management and makes independent investment decisions and has no voting power in the securities held in such client accounts. Consequently, this Statement shall not be construed as an admission by the Reporting Person that it is the beneficial owner of any of the Ordinary Shares covered by this Statement.
    (b)Percent of class:

    See Row (11) of the cover page of the Reporting Person above.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    See Row (6) of the cover page of the Reporting Person above and note in Item 4 above.

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    See Row (8) of the cover page of the Reporting Person above and note in Item 4 above.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Harel Insurance Investments & Financial Services Ltd
     
    Signature:/s/ Alon Kaufman
    Name/Title:Alon Kaufman/Vice President
    Date:02/23/2026
    Get the next $BWAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BWAY

    DatePrice TargetRatingAnalyst
    11/16/2023Outperform → Mkt Perform
    Raymond James
    3/3/2022$15.00Buy
    Loop Capital
    11/29/2021$14.00 → $15.00Buy
    HC Wainwright & Co.
    8/12/2021$17.00 → $14.00Buy
    HC Wainwright & Co.
    7/19/2021$17.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BWAY
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by BrainsWay Ltd.

    SCHEDULE 13G - Brainsway Ltd. (0001505065) (Subject)

    2/23/26 8:52:22 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by BrainsWay Ltd.

    6-K - Brainsway Ltd. (0001505065) (Filer)

    2/19/26 7:30:04 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by BrainsWay Ltd.

    6-K - Brainsway Ltd. (0001505065) (Filer)

    2/18/26 7:30:03 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BrainsWay to Participate in the Citi 2026 Unplugged MedTech and Life Sciences Access Day

    BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today announced that management will participate in one-on-one meetings at the Citi 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026, in New York, NY. Please contact your Citi representative to request a meeting at the conference. About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimu

    2/23/26 8:00:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.

    BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into a strategic equity financing agreement with BrainStim Health Inc. ("BrainStim"), a provider based in British Columbia servicing a growing number of mental health clinics in Canada. Under the terms of the agreement, BrainsWay will invest $1.0 million initial

    2/19/26 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay Reports Cigna's Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care

    BURLINGTON, Mass. and JERUSALEM, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today commented on the recent news issued by Evernorth® Behavioral Health, Inc., a division of the Cigna Group, which serves over 18 million covered lives across 12 states, that it will no longer require prior authorization for transcranial magnetic stimulation (TMS) for contracted providers whose patients have coverage under Evernorth and Cigna Healthcare® plans. The Evernorth press release stated that the change will be effective on March 6, 2026. "Evernorth's decision to eliminate

    2/18/26 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brainsway downgraded by Raymond James

    Raymond James downgraded Brainsway from Outperform to Mkt Perform

    11/16/23 7:31:55 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    Loop Capital initiated coverage on BrainsWay with a new price target

    Loop Capital initiated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00

    3/3/22 4:42:28 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on BrainsWay with a new price target

    HC Wainwright & Co. reiterated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00 from $14.00 previously

    11/29/21 6:24:14 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Financials

    Live finance-specific insights

    View All

    BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights

    Revenue increased 29% to $13.5 million in Q3 2025 as compared with Q3 2024 Operating income totaled $1.3 million and Adjusted EBITDA rose approximately 80% to $2.0 million in Q3 2025, as compared with Q3 2024 Remaining performance obligations increased to $65 million FDA cleared an accelerated protocol for Deep TMS treatment of patients with major depressive disorder (MDD) Raised midpoint of full-year 2025 Revenue and EBITDA guidance Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatm

    11/11/25 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025

    BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, November 11, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the financial results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, November 11, 2025Time:8:30 AM Eastern TimeUnited States:1-8

    10/28/25 8:00:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

    BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has entered into a strategic equity financing agreement with Axis Management Company, Inc. ("Axis Integrated Mental Health" or "Axis"), a management services organization servicing several mental health clinics in Colorado. Under the terms of the agreement, BrainsWay will invest $2.3 million initially, and an additional potential $1 million milestone-based investment, for a minority position in Axis in the form of a preferred, annually c

    8/20/25 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Leadership Updates

    Live Leadership Updates

    View All

    MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

    MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025. "Scott's extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team," said Dr. Jennifer Bath, MindWalk CEO. "His proven ability to strengthen financial systems, execute disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we scale our Bio-Native AI platform globally." Mr. Areglado brings more

    10/21/25 8:28:00 AM ET
    $BWAY
    $HYFT
    $ICAD
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer

    BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Richard A. Bermudes, M.D. as Chief Medical Officer (CMO), effective September 1, 2024. Dr. Aron Tendler, M.D., who has served as CMO since 2015, will continue to serve as a collaborator on important strategic research projects. "We are excited to have Richard join our team to lead and shape BrainsWay's clinical strategy and product roadmap. His extensive experience with TMS and brain stimulation therapies as a practicing phys

    8/29/24 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    Murchinson Takes Action to Replace Board of Directors of Nano Dimension at Upcoming Annual General Meeting

    Highlights Entrenchment Tactics Taken by the Board Before and Following March Special Meeting Where Shareholders Overwhelmingly Supported Murchinson's Case for Change – Including the Removal of CEO and Chairman Yoav Stern From the Board Puts Forward Proposals to Improve Company's Failed Corporate Governance by Seeking to Remove All Current Directors and Appoint Five New, Experienced and Independent Nominees Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 5.9% of the outstanding shares of Nano Dimension Ltd., a company incorporated in Israel (NASDAQ:NNDM) ("Nano Dimension" or th

    8/3/23 3:00:00 PM ET
    $BWAY
    $INSG
    $MCK
    Medical/Dental Instruments
    Health Care
    Telecommunications Equipment
    Telecommunications

    $BWAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

    SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

    11/14/24 1:33:58 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

    SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

    11/14/24 1:32:48 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by BrainsWay Ltd.

    SC 13D - Brainsway Ltd. (0001505065) (Subject)

    11/13/24 6:09:51 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care